Clearside Biomedical

Clearside Biomedical ROIC

Delisted

The Return on Invested Capital (ROIC) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 88.41 %. In the previous year, Return on Invested Capital (ROIC) was 204.15 % — a change of -56.69% (lower).

ROIC

88.41 %

YoY

-56.69%

Last updated:

Return on Invested Capital (ROIC) of Clearside Biomedical is 2024 88.41 % . Return on Invested Capital (ROIC) of Clearside Biomedical was 2023 204.15 % . It decreases by -56.69% lower compared to the previous year.

The Clearside Biomedical ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2017
-200.41 USD
Jan 1, 2018
-246.49 USD
Jan 1, 2019
-188.66 USD
Jan 1, 2020
-186.77 USD
Jan 1, 2021
1.00 USD
Jan 1, 2022
-310.56 USD
Jan 1, 2023
204.15 USD
Jan 1, 2024
88.41 USD
The Clearside Biomedical ROIC history
YEARROICYoY
88.41 %-56.69%
204.15 %-165.74%
-310.56 %-31,139.26%
1.00 %-100.54%
-186.77 %-1.00%
-188.66 %-23.46%
-246.49 %+22.99%
-200.41 %+513.69%
-32.66 %-69.20%
-106.01 %-20.73%
-133.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Return on Invested Capital (ROIC) of Clearside Biomedical is 88.41 % in 2024.

Return on Invested Capital (ROIC) of Clearside Biomedical changed from 204.15 % to 88.41 %, representing a -56.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clearside Biomedical

All Key Metrics — Clearside Biomedical